In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos NV

www.glpg.com

Latest From Galapagos NV

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

EU Approvals In Sight For Novartis, Roche, and Janssen

EU approval is a formality for the eight products given the nod this week at the European Medicines Agency. There's no word, though, on filgotimid, from Gilead/Galapagos.

Europe BioPharmaceutical

EU Approval Nod Possible For Novartis, Gilead/Galapagos, and Janssen

The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.

Europe Drug Review

SELECTION Positive For Gilead/Galapagos’s Filgotinib In UC But Will It Be Enough To Compete?

Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Galapagos Genomics NV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Galapagos NV
  • Senior Management
  • Onno van de Stolpe, CEO
    Bart Filius, CFO & COO
    Andre Hoekema, PhD, CBO
    Piet Wigerinck, PhD, CSO
    Walid Abi-Saab, MD, CMO
    Michele Manto, Chief Commercial Officer
  • Contact Info
  • Galapagos NV
    Phone: (32) 15 34 29 00
    Generaal De Wittelaan L11 A3
    Mechelen, 2800
    Belgium
UsernamePublicRestriction

Register